MeSH tree: D12.776.377.715.548.114.224.200.798
A patient's own immune cells, multiplied into an army of billions of immune cells in a lab, can be used as a living medicine against metastatic melanoma, an aggressive form of skin cancer, as the TIL trial has shown. The ...
Dec 8, 2022
0
61
Patients with high-risk stage III-IV melanoma who received pembrolizumab after their surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose ...
Nov 23, 2022
0
83
Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel ...
Nov 16, 2022
0
56
A single research test has the potential to predict which patients treated with immunotherapies—which harness the immune system to attack cancer cells—are likely to have their cancer recur or have severe side effects, a new ...
Sep 15, 2022
0
90
Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrectomy relapse, according ...
Sep 14, 2022
0
43
A physician-scientist at City of Hope, one of the largest cancer research and treatment organizations in the United States, has identified a novel combination immunotherapy regimen that demonstrated significant response in ...
Sep 12, 2022
0
73
Merkel cell carcinoma is a rare but aggressive form of skin cancer that has a high rate of metastasis and poor patient outcomes. The current standard of care for patients with recurrent, unresectable or metastatic disease ...
Sep 12, 2022
0
54
A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported ...
Sep 11, 2022
0
68
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer ...
Sep 8, 2022
0
69
